X
Galapagos shares surge on RA drug trial results
https://pharmaphorum.com/news/galapagos-shares-surge-drug-trial-results/
Rheumatoid arthritis
Biosimilars underused in rheumatoid arthritis on the NHS – experts
Experts call for lower disease activity threshold for biologic drugs
Celltrion hopes to outdo inflammatory disease rivals with SC infliximab
Drugmaker could file in EU in coming weeks, according to report
More good news for AbbVie in rheumatoid arthritis
AbbVie has reported positive top-line results for its oral JAK1-selective inhibitor in rheumatoid arthritis (RA), bringing it closer to a potential new early treatment option for patients.
Blow for Lilly after FDA panel uncertain over RA drug bariticinib
Doubts over marketability of drug if it is approved
Lilly axes trial of Hanmi’s arthritis drug
Lilly may decide to develop drug in other indications
Digital health round-up: online tool raises awareness of RA heart risks
Richard Staines gives a round-up of the latest developments in digital health.
Payday for AbbVie as Humira biosimilar delayed for five years
Deal with Amgen signals exclusivity until 2023 for mega-blockbuster
